



Company release No 29/2016

Hørsholm
2 December 2016

Notification of ownership in ALK

Page 1/1

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 29 of the Danish Securities Trading Act, ALK has received notification from Jupiter Asset Management Ltd., that Jupiter Asset Management Ltd. in its capacity as investment manager for a number of clients now holds more than 5% of the share capital of ALK-Abelló A/S.

Jupiter Asset Management Ltd. now owns 5% of the company share capital equivalent to 506,562 B shares.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,200 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, South-East Asia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.